Kadmon Holdings Llc (KDMN) 8.00 $KDMN Kadmon In
Post# of 273321
Posted On: 09/25/2016 11:05:42 AM
Kadmon Holdings Llc (KDMN) 8.00 $KDMN
Kadmon Initiates Placebo-Controlled Phase 2 Clinical Trial Evaluating KD025 in Psoriasis
BusinessWire - Wed Sep 21, 3:47PM CDT
Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the first patient has been dosed in a double-blind, placebo-controlled Phase 2 clinical trial of KD025, the Company's oral inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), in moderate to severe chronic plaque psoriasis. The dose-finding study examines KD025 administered at four doses: 200 mg once daily (QD), 200 mg twice daily (BID), 400 mg QD and 600 mg QD (administered as 400 mg in the morning and 200 mg in the evening) compared to matching placebo BID for 16 weeks in approximately 150 patients in the United States.
KDMN: 8.00 (+0.24)
Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 in Chronic Graft-Versus Host Disease
BusinessWire - Wed Sep 21, 3:04PM CDT
Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the first patient has been dosed in a Phase 2 clinical trial of KD025, the Company's rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, for the treatment of chronic graft-versus-host disease (cGVHD). The randomized, open-label, 24-week study examines the safety, tolerability and activity of KD025 dosed at 200 mg once daily (QD), 200 mg twice daily (BID) or 400 mg QD in 48 cGVHD patients in the United States.
KDMN: 8.00 (+0.24)
Kadmon Reports Financial and Operational Results for the Three and Six Months Ended June 30, 2016
BusinessWire - Wed Sep 07, 3:01PM CDT
Kadmon Holdings, Inc. (NYSE:KDMN), a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need, today reported its financial and operational results for the three and six months ended June 30, 2016.
KDMN: 8.00 (+0.24)
Kadmon to Present at Two Upcoming Investor Conferences
BusinessWire - Wed Sep 07, 8:00AM CDT
Kadmon Holdings, Inc. (NYSE:KDMN), today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present an overview of the Company and its clinical programs at two upcoming investor conferences in New York:
KDMN: 8.00 (+0.24)
Kadmon Initiates Phase 2 Clinical Trial Evaluating Tesevatinib in Glioblastoma
BusinessWire - Mon Aug 29, 8:00AM CDT
Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the first patient has been dosed in a Phase 2 clinical trial of tesevatinib, the Company's oral tyrosine kinase inhibitor, for the treatment of recurrent glioblastoma. The open-label, multicenter study examines tesevatinib monotherapy administered at 300 mg once daily in up to 40 patients in the United States.
KDMN: 8.00 (+0.24)
Kadmon Initiates Placebo-Controlled Phase 2 Clinical Trial Evaluating KD025 in Psoriasis
BusinessWire - Wed Sep 21, 3:47PM CDT
Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the first patient has been dosed in a double-blind, placebo-controlled Phase 2 clinical trial of KD025, the Company's oral inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), in moderate to severe chronic plaque psoriasis. The dose-finding study examines KD025 administered at four doses: 200 mg once daily (QD), 200 mg twice daily (BID), 400 mg QD and 600 mg QD (administered as 400 mg in the morning and 200 mg in the evening) compared to matching placebo BID for 16 weeks in approximately 150 patients in the United States.
KDMN: 8.00 (+0.24)
Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 in Chronic Graft-Versus Host Disease
BusinessWire - Wed Sep 21, 3:04PM CDT
Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the first patient has been dosed in a Phase 2 clinical trial of KD025, the Company's rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, for the treatment of chronic graft-versus-host disease (cGVHD). The randomized, open-label, 24-week study examines the safety, tolerability and activity of KD025 dosed at 200 mg once daily (QD), 200 mg twice daily (BID) or 400 mg QD in 48 cGVHD patients in the United States.
KDMN: 8.00 (+0.24)
Kadmon Reports Financial and Operational Results for the Three and Six Months Ended June 30, 2016
BusinessWire - Wed Sep 07, 3:01PM CDT
Kadmon Holdings, Inc. (NYSE:KDMN), a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need, today reported its financial and operational results for the three and six months ended June 30, 2016.
KDMN: 8.00 (+0.24)
Kadmon to Present at Two Upcoming Investor Conferences
BusinessWire - Wed Sep 07, 8:00AM CDT
Kadmon Holdings, Inc. (NYSE:KDMN), today announced that Harlan W. Waksal, M.D., President and Chief Executive Officer, will present an overview of the Company and its clinical programs at two upcoming investor conferences in New York:
KDMN: 8.00 (+0.24)
Kadmon Initiates Phase 2 Clinical Trial Evaluating Tesevatinib in Glioblastoma
BusinessWire - Mon Aug 29, 8:00AM CDT
Kadmon Holdings, Inc. (NYSE:KDMN) today announced that the first patient has been dosed in a Phase 2 clinical trial of tesevatinib, the Company's oral tyrosine kinase inhibitor, for the treatment of recurrent glioblastoma. The open-label, multicenter study examines tesevatinib monotherapy administered at 300 mg once daily in up to 40 patients in the United States.
KDMN: 8.00 (+0.24)
(0)
(0)